期刊文献+

吡格列酮治疗2型糖尿病的疗效及安全性的临床观察 被引量:1

吡格列酮治疗2型糖尿病的疗效及安全性的临床观察
下载PDF
导出
摘要 通过观察将30例2型糖尿病患者随机分为治疗组和对照组,治疗组加用吡格列酮28mg,每天早餐前30min口服,对照组加用安慰剂,疗程均10周。观察2组治疗前后糖、脂代谢相关指标的变化。最后得出吡格列酮对降低2型糖尿病患者的血糖、血脂,改善胰岛素抵抗有良好疗效。 Through the observation in 30 cases of type 2 diabetes patients were randomly divided into the treatment group and control group,the treatment group by pioglitazone 28 mg daily,half an hour before the breakfast,combined with placebo in oral treatment are 10 weeks.Observation treatment sugar,lipid metabolism related indexes of change.Finally draw pioglitazone reduces in patients with type 2 diabetes,improve blood glucose and insulin resistance has good curative effect.
作者 杨华
出处 《中外医疗》 2010年第36期121-121,123,共2页 China & Foreign Medical Treatment
关键词 吡格列酮 2型糖尿病 疗效及安全性 临床观察 Pioglitazone Type 2 diabetes Curative effect and safety Clinical observation
  • 相关文献

参考文献5

二级参考文献18

  • 1[1]Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study(UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin endocrinol Diabetes, 1998; 106:369~372. 被引量:1
  • 2[2]Haffner SM. Epdemiology of insulin resistance and its relation to coronary artery disease. American J Cardiology, 1999; 84:11 ~ 14. 被引量:1
  • 3[3]Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferactor-activated receptor γ. J Biol Chem, 1995; 270:129~153. 被引量:1
  • 4[4]Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes,1997; 46:1393~ 1399. 被引量:1
  • 5[5]Kemnitz JW, Elson DF, Roecker EB, et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels,and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes, 1994; 43:204~211. 被引量:1
  • 6[6]Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther, 2001; 23:1792~1823. 被引量:1
  • 7[7]Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis, 2001; 12:413~423. 被引量:1
  • 8[8]Hanefeld M, Belcher G. Safety profile of pioglitazone. Iht J Clin Pract, 2001, 121:27~31. 被引量:1
  • 9[9]Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf, 2001; 24 873~888. 被引量:1
  • 10[10]Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.Clin Ther, 2000; 22:1395~1409. 被引量:1

共引文献114

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部